Lv1
70 积分 2022-05-13 加入
Real-world incidence and risk of myelodysplastic syndrome and acute myeloid leukemia secondary to PARP inhibitors in ovarian cancer
6天前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
1个月前
已完结
Polymer‐PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High‐Grade Serous Ovarian Cancer
1个月前
已完结
Subgroup Analyses in Clinical Trials
1个月前
已完结
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials
1个月前
已完结
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis
1个月前
已完结
PARPi, BRCA, and gaps: controversies and future research
2个月前
已完结
Breaking BRCA Apart – How important is mutation location and shape in influencing outcome?
2个月前
已关闭
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
2个月前
已完结
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
2个月前
已完结
皖公网安备34019202002308
